The Cost Effectiveness of Partially Effective HIV Vaccines

  • Douglas K. Owens
  • Donna M. Edwards
  • John F. Cavallaro
  • Ross D. Shachter
Part of the International Series in Operations Research & Management Science book series (ISOR, volume 70)


Development of a vaccine remains the best hope for curtailing the worldwide pandemic caused by human immunodeficiency virus (HIV) infection. Due to the complex biology of HIV infection, there is increasing concern that an HIV vaccine may provide incomplete protection from infection. In addition to reducing susceptibility to disease, an HIV vaccine may also prolong life in people who acquire HIV despite vaccination, and may reduce HIV transmission. We evaluated how varying degrees of vaccine efficacy for susceptibility, progression of disease, and infectivity influence the costs and benefits of a vaccine program in a population of men who have sex with men, We found that the health benefits, and thus cost effectiveness, of HIV vaccines were strikingly dependent on each of the types of vaccine efficacy. We also found that vaccines with even modest efficacy provided substantial health benefits and were cost effective or cost saving. Although development of an HIV vaccine has been extremely difficult, even a partially effective HIV vaccine could dramatically change the course of the HIV epidemic.

Key words

HIV Vaccines Cost-effectiveness analysis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    UNAIDS Joint United Nations Programme on HIV/AIDS (2002). AIDS Epidemic Update,, Accessed February 16, 2003.
  2. [2]
    Hu, D.J., C.R. Vitek, B. Bartholow, and T.D. Mastro (2003). Key issues for a potential human immunodeficiency virus vaccine. Clinical Infectious Diseases, 36, 638–644.CrossRefPubMedGoogle Scholar
  3. [3]
    Longini, I.M., Jr., S. Datta, and M.E. Halloran (1996). Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines. Journal on AIDS and Human Retrovirology, 13, 440–447.Google Scholar
  4. [4]
    Halloran, M.E., C.J. Struchiner, and I.M. Longini, Jr. (1997). Study designs for evaluating different efficacy and effectiveness aspects of vaccines. American Journal of Epidemiology, 146, 789–803.PubMedGoogle Scholar
  5. [5]
    Datta, S., M.E. Halloran, and I.M. Longini, Jr. (1998). Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy. Statistics in Medicine, 17, 185–200.CrossRefPubMedGoogle Scholar
  6. [6]
    Gray, R.H., et al. (2001). Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. The Lancet, 357, 1149–1153.Google Scholar
  7. [7]
    Quinn, T.C., et al. (2000). Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. New England Journal of Medicine, 342, 921–929.CrossRefPubMedGoogle Scholar
  8. [8]
    Edwards, D.M., R.D. Shachter, and D.K. Owens (1998). A dynamic HIV-transmission model for evaluating the costs and benefits of vaccine programs. Interfaces, 28, 144–166.Google Scholar
  9. [9]
    Owens, D.K., D.M. Edwards, and R.D. Shachter (1998). Population effects of preventive and therapeutic HIV vaccines in early-and late-stage epidemics. AIDS, 12, 1057–1066.CrossRefPubMedGoogle Scholar
  10. [10]
    Owens, D.K., D.M. Edwards, and R.D. Shachter (2001). Costs and benefits of imperfect HIV vaccines: Implications for vaccine development and use, in Quantitative Evaluation of HIV Prevention Programs, E.H. Kaplan and R. Brookmeyer, Eds., Yale Press, New Haven, CT.Google Scholar
  11. [11]
    Owens, D.K. and H.C. Sox (2000). Medical Decision Making: Probabilistic Medical Reasoning, in Medical Informatics: Computer Applications in Health Care and Biomedicine, E.H. Shortliffe, et al., Eds., Springer-Verlag, New York.Google Scholar
  12. [12]
    Gold, M., J.E. Siegel, L.B. Russell, and M.C. Weinstein, Eds. (1996). Cost-Effectiveness in Health and Medicine. Oford University Press, New York.Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Douglas K. Owens
    • 1
    • 2
  • Donna M. Edwards
    • 3
  • John F. Cavallaro
    • 4
  • Ross D. Shachter
    • 4
  1. 1.VA Palo Alto Health Care SystemPalo Alto
  2. 2.Center for Primary Care and Outcomes ResearchStanford University School of MedicineStanford
  3. 3.Sandia National LaboratoriesLivermore
  4. 4.Department of Management Science and EngineeringStanford UniversityStanford

Personalised recommendations